ESMO Symposium on Immuno-Oncology 2016

Oncology Meeting Resources

04 Nov - 06 Nov, Lausanne, Switzerland

ESMO Immuno Oncology 2016 Square

ESMO Symposium on Immuno-Oncology 2016 underlined ESMO’s commitment to educate cancer physicians and researchers in a rapidly evolving area of treating cancer through immunotherapy and offered an update on the latest developments in immuno-oncology in an effort to bring innovative approaches directly to patients.

Abstracts, presentations and webcasts from the ESMO Symposium on Immuno-Oncology 2016 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
Marco Gerlinger Impact of tumour heterogeneity Cancer antigens
Omid Hamid We belong together: Combinations of checkpoint inhibitors Immuno-oncology meets molecular oncology
Ignacio Melero Combination of checkpoints and immunostimulation Immuno-oncology meets molecular oncology
Sander Bins 1O - Association between single nucleotide polymorphisms and side effects in nivolumab treated NSCLC patients Proffered paper session
Chia-Chi Lin 2O - Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results Proffered paper session
John Haanen Invited discussant abstracts 1O and 2O Proffered paper session
Chi Zhang 3O - Generation of immune checkpoint knock-out human antigen-specific T cells via CRISPR/Cas9-mediated genetic engineering Proffered paper session
Cristian Capasso 4O - Enhanced anti-cancer vaccines with a new epitope improvement system Proffered paper session
Jonathan Back 5O - GBR1302-BEAT ® bispecific antibody targeting CD3 and HER2 demonstrates a higher anti-tumor potential than current HER2-targeting therapies Proffered paper session
William Grossman Cancer Immunotherapy Combinations: Attacking tumour immune escape mechanisms Beyond PD-1/PD-L1 axis blockade: Combinations or new molecules
David Berman Stimulation of anti-cancer immunity by new mechanisms and combinations Beyond PD-1/PD-L1 axis blockade: Combinations or new molecules
Robert Andtbacka Herpes Simplex and Coxsackie viruses oncolytic immunotherapy: Changing the treatment of advanced cancer Biological therapy: Infectious agents at the service of immunotherapy
Thomas Dubensky Activation of the STING pathway to induce tumor immunity Biological therapy: Infectious agents at the service of immunotherapy
Cristian Capasso 6PD - Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines Poster discussion session
Suvi Parviainen 7PD - Oncolytic immunotherapy for enabling dendritic cell therapy Poster discussion session